Setmelanotide dosage: reported doses and schedule

Typical reported dose: Genetic obesity, age 12+: starts at 2 mg once daily

• FDA: genetic obesity, age 12+: 2 mg once daily, then 3 mg once daily once daily, under the skin. Drug label. Studied in: BBS or genetically confirmed POMC, PCSK1 or LEPR deficiency; age ≥12. (source)
• FDA: acquired hypothalamic obesity: 0.5 mg once daily, then 1 mg once daily, then 2 mg once daily, then 3 mg once daily once daily, under the skin. Drug label. Studied in: Acquired hypothalamic obesity; age ≥6 years. (source)
• FDA: genetic obesity, ages 6–11: 1 mg once daily, then 2 mg once daily, then 3 mg once daily once daily, under the skin. Drug label. Studied in: BBS or POMC, PCSK1 or LEPR deficiency; age 6 to <12. (source)
• FDA: young children, baseline weight 15 to <20 kg: 0.5 mg once daily once daily, under the skin. Drug label. Studied in: Baseline weight 15 to <20 kg; genetic obesity age 2–5, or acquired hypothalamic obesity age 4–5. (source)
• FDA: young children, baseline weight 20 to <30 kg: 0.5 mg once daily, then 1 mg once daily once daily, under the skin. Drug label. Studied in: Baseline weight 20 to <30 kg; genetic obesity age 2–5, or acquired hypothalamic obesity age 4–5. (source)
• FDA: young children, baseline weight 30 to <40 kg: 0.5 mg once daily, then 1 mg once daily, then 1.5 mg once daily once daily, under the skin. Drug label. Studied in: Baseline weight 30 to <40 kg; genetic obesity age 2–5, or acquired hypothalamic obesity age 4–5. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator